Table 1 The correlation of CHIP and TRAF2 expression with the clinical characteristics of GC patients
From: The ubiquitin ligase CHIP modulates cellular behaviors of gastric cancer cells by regulating TRAF2
Characteristics | Nr. of patients n = 100 | CHIP expression | TRAF2 expression | ||||
|---|---|---|---|---|---|---|---|
Low n = 66 (66%) | High n = 34 (34%) | p value | Low n = 47 (47%) | High n = 53 53%) | p value | ||
Age (years) | Â | Â | Â | 0.158 | Â | Â | 0.106 |
 Median | 65 (32–81) |  |  |  |  |  |  |
 ≤ 65 | 51 | 37 (72.5) | 14 (27.5) |  | 28 (54.9) | 23 (45. 1) |  |
 > 65 | 49 | 29 (59.2) | 20 (40.8) |  | 19 (38.8) | 30 (61.2) |  |
Gender | Â | Â | Â | 0.225 | Â | Â | 0.102 |
 Male | 64 | 45 (70.3) | 19 (29.7) |  | 34 (53.1) | 30 (46.9) |  |
 Female | 36 | 21 (58.3) | 15 (41.7) |  | 13 (36.1) | 23 (63.9) |  |
Tumor diameter (cm) | Â | Â | Â | 0.327 | Â | Â | 0.067 |
 ≤ 5 | 52 | 32 (61.5) | 20 (38.5) |  | 29 (55.8) | 23 (44.2) |  |
 > 5 | 48 | 34 (70.8) | 14 (29.2) |  | 18 (37.5) | 30 (62.5) |  |
Site of tumor | Â | Â | Â | 0.341 | Â | Â | 0.064 |
 Cardia | 13 | 6 (46.2) | 7 (53.8) |  | 4 (30.8) | 9 (69.2) |  |
 Body | 28 | 21 (75) | 7 (25) |  | 16 (57.1) | 12 (42.9) |  |
 Antrum | 51 | 34 (66.7) | 17 (33.3) |  | 26 (51.0) | 25 (49.0) |  |
 Unknown | 8 | 5 (62.5) | 3 (37.5) |  | 1 (12.5) | 7 (87.5) |  |
Histological types | Â | Â | Â | 0.541 | Â | Â | 0.004** |
 Tubular adenocarcinoma | 66 | 41 (62.1) | 25 (37.9) |  | 26 (39.4) | 40 (60.6) |  |
 Mucinous adenocarcinoma | 10 | 8 (80.0) | 2 (20.0) |  | 8 (80.0) | 2 (20.0) |  |
 Signet ring cell adenocarcinoma | 11 | 7 (63.6) | 4 (36.4) |  | 9 (81.8) | 2 (18.2) |  |
 Undifferentiated carcinoma | 13 | 10 (76.9) | 3 (23.1) |  | 4 (30.8) | 9 (69.2) |  |
Tumor differentiation | Â | Â | Â | 0.133 | Â | Â | 0.017* |
 Well | 15 | 8 (53.3) | 7 (46.7) |  | 10 (66.7) | 5 (33.3) |  |
 Moderate | 74 | 49 (66.2) | 25 (33.8) |  | 35 (47.3) | 39 (52.7) |  |
 Poor | 11 | 9 (81.8) | 2 (18.2) |  | 2 (18.2) | 9 (81.8) |  |
TÂ classification | Â | Â | Â | 0.000*** | Â | Â | 0.005** |
 T1–T2 | 15 | 4 (26.7) | 11 (73.3) |  | 12 (80.0) | 3 (20.0) |  |
 T3–T4 | 85 | 62 (72.9) | 23 (27.1) |  | 35 (41.2) | 50 (58.8) |  |
NÂ classification | Â | Â | Â | 0.004** | Â | Â | 0.000*** |
 N0–N1 | 42 | 21 (50.0) | 21 (50.0) |  | 30 (71.4) | 12 (28.6) |  |
 N2–N3 | 58 | 45 (77.6) | 13 (22.4) |  | 17 (29.3) | 41 (70.7) |  |
MÂ classification | Â | Â | Â | 0.250 | Â | Â | 0.056 |
 M0 | 91 | 58 (63.7) | 33 (36.3) |  | 46 (50.5) | 45 (49.5) |  |
 M1 | 9 | 8 (88.9) | 1 (11.1) |  | 1 (11.1) | 8 (88.9) |  |
TNM stage | Â | Â | Â | 0.001*** | Â | Â | 0.000*** |
 I–II | 42 | 20 (47.6) | 22 (52.4) |  | 32 (76.2) | 10 (23.8) |  |
 III–IV | 58 | 46 (79.3) | 12 (20.7) |  | 15 (25.9) | 43 (74.1) |  |